Literature DB >> 3987137

Neuromuscular complications in patients given Pavulon (pancuronium bromide) during artificial ventilation.

A A Op de Coul, P C Lambregts, J Koeman, M J van Puyenbroek, H J Ter Laak, A A Gabreëls-Festen.   

Abstract

This paper reports on 12 patients in a 3-year period (from 1st July 1980 to 1st July 1983) who were treated with artificial ventilation and with the muscle relaxant pancuronium bromide (Pavulon), over a period of 6 days or longer. After discontinuation of this drug these patients developed severe tetraparesis with areflexia, sometimes combined with disturbances of the extraocular and facial muscles and diffuse muscular atrophy, without sensory disturbances. Seven patients recovered completely after 2-5 months, two made an incomplete recovery and three died due to the primary disease. It is suggested that these neuromuscular complications were caused by prolonged high-dosage Pavulon treatment in combination with renal and hepatic disturbances and/or the use of aminoglucosides.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3987137     DOI: 10.1016/0303-8467(85)90060-5

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  28 in total

1.  Full-cost determination of different levels of care in the intensive care unit. An activity-based costing approach.

Authors:  J J Doyle; J P Casciano; S R Arikian; J Mauskopf; J E Paul
Journal:  Pharmacoeconomics       Date:  1996-10       Impact factor: 4.981

Review 2.  Drugs and brain death.

Authors:  M Kennedy; N Kiloh
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

Review 3.  Adverse neurologic effects of glucocorticosteroids.

Authors:  D Lacomis; M A Samuels
Journal:  J Gen Intern Med       Date:  1991 Jul-Aug       Impact factor: 5.128

4.  Critical illness polyneuropathy in multiple organ dysfunction syndrome and weaning from the ventilator.

Authors:  F S Leijten; A W De Weerd; D C Poortvliet; V A De Ridder; C Ulrich; J E Harink-De Weerd
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

5.  Polyneuropathies in critically ill patients: a prospective evaluation.

Authors:  K Berek; J Margreiter; J Willeit; A Berek; E Schmutzhard; N J Mutz
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

Review 6.  Neuromuscular transmission and its pharmacological blockade. Part 4: Use of relaxants in paediatric and elderly patients, in obstetrics, and in the intensive care unit.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

7.  Muscle Regeneration after Critical Illness: Are Satellite Cells the Answer?

Authors:  Michael I Polkey; Mark J Griffiths; Paul R Kemp
Journal:  Am J Respir Crit Care Med       Date:  2016-10-01       Impact factor: 21.405

8.  Risk factors for critical illness polyneuromyopathy.

Authors:  J Bednarík; P Vondracek; L Dusek; E Moravcova; I Cundrle
Journal:  J Neurol       Date:  2005-03-30       Impact factor: 4.849

9.  Preliminary observations on the neuromuscular abnormalities in patients with organ failure and sepsis.

Authors:  J H Coakley; K Nagendran; M Honavar; C J Hinds
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

Review 10.  Neuromuscular complications of sepsis.

Authors:  C F Bolton
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.